首页> 外文OA文献 >Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

【2h】

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

机译：与甲野生型左侧转移结直肠癌患者患者的六孢子素或贝伐单抗结合的第一线Folfiri成本效果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jiaqi Han; Desheng Xiao; Chongqing Tan; Xiaohui Zeng; Huabin Hu; Shan Zeng; Qin Jiang; Longjiang She; Linli Yao; Li Li; Lanhua Tang; Jian Ma; Jin Huang; Liangfang Shen;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer [J] . Jiaqi Han Cancer control : . 2020,第1期

机译：与甲野生型左侧转移结直肠癌患者患者的六孢子素或贝伐单抗结合的第一线Folfiri成本效果分析
2. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro) [J] . Michl M., Stintzing S., Fischer von Weikersthal L., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第8期

机译：在接受一线FOLFIRI加西妥昔单抗或贝伐单抗治疗的KRAS外显子2野生型和扩展RAS野生型转移性结直肠癌患者中，CEA反应与肿瘤反应和生存相关（FIRE-3试验）（aEuro）
3. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J] . PietrantonioF., GarassinoM.C., TorriV., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第10期

机译：答复德国AIO随机研究KRK-0306中FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS突变肿瘤患者亚组分析
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Comparative Analysis on Innate Immune System Function in Metastatic Breast, Colorectal, and Prostate Cancer Patients with Circulating Tumor Cells [D] . Santos, Mark Anthony Francisco. 2014

机译：转移性乳腺癌，结直肠癌和前列腺癌患者循环肿瘤细胞先天免疫系统功能的比较分析
6. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined WithCetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided MetastaticColorectal Cancer [O] . Jiaqi Han, Desheng Xiao, Chongqing Tan, 2020

机译：一线FOLFIRI结合的成本效果分析。RAS野生型左侧转移患者西妥昔单抗或贝伐单抗大肠癌
7. PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia [O] . Vargas-Valencia J, Garcia Perlaza J 2015

机译：帕尼单抗+ Folfox与西妥昔单抗+ Folfiri相比一线治疗PCN171成本效益分析

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅